- Benign hematologic disorder
- Bladder cancer
- Kidney cancer
- Melanoma
- Melanoma skin cancer
- Merkel cell skin cancer
- Penile cancer
- Prostate cancer
- Skin basal cell carcinoma
- Skin cancer
- Squamous cell skin cancer
- Testicular cancer
Jason E. Shpilsky, MD
Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Cherry Hill
Penn Medicine Provider
About me
- Clinical Assistant Professor of Medicine (Hematology-Oncology)
My education and training
- Medical School: Temple University
- Residency: Beth Israel Deaconess Medical Center
- Fellowship: Beth Israel Deaconess Medical Center
Spoken languages
English
English
Reviews
1232 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Amerihealth of NJ Core
- Amerihealth of NJ Enhanced
- Amerihealth of NJ HMO
- Amerihealth of NJ Local Value
- Amerihealth of NJ POS
- Amerihealth of NJ PPO
- Amerihealth of NJ Regional Preferred
- Amerihealth of NJ Secure
- Amerihealth of NJ Ultimate (PPO)
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Qualifications and experience
- Hematology, 2023
- Medical Oncology, 2022
- Internal Medicine, 2018
- Alpha Omega Alpha, Local
- American Medical Association, National
- American Society of Clinical Oncology, National
- American Society of Hematology, National
- Abramson Cancer Center
- Penn Genitourinary and Urologic Cancer Program
- Penn Melanoma and Cutaneous Malignancies Program
Treatments and conditions
Research
Publications
Demissei BG, Ko K, Huang A, Lee DJ, Doucette AG, Smith AM, Wilcox NS, Reibel J, Sun L, Agarwal M, Haas NB, Hollis G, Shpilsky JE, Takvorian SU, Vaughn DJ, Chen J, Hubbard RA, Powell-Wiley T, Yancy C, Narayan V, Ky B. Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer , JACC CardioOncol, 6(3): 2024,390-401
Roberts DA, Faig J, Bodio-Downey K, Shpilsky J, Leahy K, Wischhusen J, Giordano S, Acharya U, Drews R, Dougherty D, Lathan C, Rangachari D. Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future , JCO Oncol Pract, 19(6): 2023,e927-e934.
Shpilsky J, Stevens J, Bubley G. An up-to-date evaluation of abiraterone for the treatment of prostate cancer , Expert Opin Pharmacother, 22(10): 2021,1227-1234.
Rakowsky S, Flashner BM, Doolin J, Reese Z, Shpilsky J, Yang S, Smith CC, Graham K. Five Questions for Residency Leadership in the Time of COVID-19: Reflections of Chief Medical Residents From an Internal Medicine Program , Acad Med, 95(8): 2020,1152-1154
Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples , J Thorac Oncol, 14(11): 2019,1995-2002